Nrf2 activator PB125® as a carnosic acid-based therapeutic agent against respiratory viral diseases, including

Joe M McCord1, Brooks M Hybertson1, Adela Cota-Gomez2

  • 1Pathways Bioscience, Aurora, CO, 80045, USA; Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.

Insights

PB125®, a phytochemical, activates Nrf2 (nuclear factor erythroid 2-related factor 2) to maintain metabolic balance. This Nrf2 activation helps combat health issues from aging and environmental factors, including infections.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key transcription factor regulating metabolic balance and cellular defense.
  • Nrf2 activity is crucial for maintaining redox homeostasis, which can be compromised by aging, toxins, and infections.
  • Declining Nrf2 levels with age impair the body's ability to manage metabolic dysregulation and increase susceptibility to pathologies.

Purpose of the Study:

  • To review the therapeutic potential of Nrf2 activators, focusing on phytochemical compositions like PB125®.
  • To examine gene expression patterns associated with pulmonary infections and their modulation by Nrf2.
  • To highlight the role of phytochemicals in enhancing Nrf2 activation for normalizing metabolic pathways.

Main Methods:

  • Literature review of Nrf2 activators and their mechanisms of action.
  • Analysis of gene expression dysregulation in pulmonary infections.
  • Examination of phytochemical effects on Nrf2 pathways.

Main Results:

  • PB125® demonstrates potent Nrf2 activation and direct cellular actions.
  • Nrf2 activation is vital for mitigating metabolic disruption caused by various stressors.
  • Phytochemicals can therapeutically increase Nrf2 levels, counteracting age-related decline and infection susceptibility.

Conclusions:

  • Nrf2 activators, particularly phytochemicals, hold significant therapeutic promise for metabolic and infectious diseases.
  • Targeting Nrf2 pathways offers a strategy to address age-related decline in metabolic regulation.
  • Judicious use of phytochemicals can restore redox balance and normalize gene expression during pathological conditions.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
8.0K
Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
1.1K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.0K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
764
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.7K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
596